GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (HKSE:00512) » Definitions » 14-Day RSI

Grand Pharmaceutical Group (HKSE:00512) 14-Day RSI : 80.22 (As of May. 18, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Grand Pharmaceutical Group 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-18), Grand Pharmaceutical Group's 14-Day RSI is 80.22.

The industry rank for Grand Pharmaceutical Group's 14-Day RSI or its related term are showing as below:

HKSE:00512's 14-Day RSI is ranked worse than
97.54% of 1140 companies
in the Drug Manufacturers industry
Industry Median: 50.41 vs HKSE:00512: 80.22

Competitive Comparison of Grand Pharmaceutical Group's 14-Day RSI

For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grand Pharmaceutical Group's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Grand Pharmaceutical Group's 14-Day RSI falls into.



Grand Pharmaceutical Group  (HKSE:00512) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grand Pharmaceutical Group  (HKSE:00512) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Grand Pharmaceutical Group 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Grand Pharmaceutical Group (HKSE:00512) Business Description

Traded in Other Exchanges
Address
99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG
Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from China and also has a presence in America; Europe; Asia other than the PRC and others.

Grand Pharmaceutical Group (HKSE:00512) Headlines

No Headlines